Market ResearchApril 8, 2024 Missouri Considers $10 Million from Opioid Settlements for Psilocybin Research
PressApril 5, 2024 Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization
Market ResearchApril 4, 2024 FSD Pharma Cuts Annual Losses to $18Million; Will Need More Capital to Develop
PressApril 4, 2024 Red Light Holland Partners with Professor David Nutt and Drug Science to Analyze iMicroapp Data and Promote Responsible Regulations For Psilocybin Microdosing
PressApril 3, 2024 Filament Health To Discuss Its Drug Development Platform in Fireside Chat With Water Tower Research on April 4, 2024 at 12PM ET
PressApril 3, 2024 Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic
PressApril 3, 2024 Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference
PressApril 3, 2024 BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001
PressApril 2, 2024 PsyCan Welcomes Expansion of Insurance Coverage for Psychedelic-Assisted Therapy in Alberta
PressApril 2, 2024 Compass Pathways To Participate in Upcoming 23rd Annual Needham Virtual Healthcare Conference
PressApril 1, 2024 Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset
PressMarch 28, 2024 Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
PressMarch 28, 2024 atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
PressMarch 28, 2024 Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference
